Dr Reddys Laboratories Ltd (DRREDDY) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management is confident of relaunching Semaglutide in November 2026, with the API scale-up issue now resolved and orders ready to be fulfilled.
- For the key Abatacept biosimilar launch, management is preparing for a December approval and believes a 15-25% market share is achievable for the IV version.
- The company reiterated its ability to sustain a 20%+ EBITDA margin, which could rise to over 21% with a successful Semaglutide launch.
Performance Overview
- Reported a 1.5% year-over-year decline in revenue, but the underlying base business, excluding Lenalidomide in North America, demonstrated double-digit growth.
- Achieved a consolidated EBITDA margin of 20.6%, supported by a favorable business mix and cost control measures.
- Progress on key strategic assets remains on track, including the planned relaunch of Semaglutide in November 2026 and the upcoming PDUFA date for Abatacept in December 2026.
- Strengthened its portfolio through new product launches, partnerships, and approvals, including a dengue vaccine collaboration with Takeda and USFDA approval for Rituximab biosimilar.
- Maintained strong performance in core markets like India and Emerging Markets, with both segments delivering robust double-digit year-over-year growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.